Skip to main content
Fig. 4 | Journal of Biomedical Science

Fig. 4

From: Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine

Fig. 4

CNGRC-yCD fusion protein has high binding affinity to APN-expressing cells. a-b. HT-1080 a, and HT-29 b. cells were cultured on a 96-well plate. CNGRC-yCD or yCD protein (0.0625, 0.125, 0.25, 0.5, 1.0 and 2.0 μM) was added into the wells to determine its specific binding affinity by ELISA assay using horseradish peroxidase (HRP)–tagged anti-His6 antibody. c-d. High- c. and low- d. APN-expressing cells were cultured on a 96-well plate. 2.0 μM of yCD or CNGRC-yCD protein was added into the wells and the binding capacities of both proteins were determined by ELISA assay using horseradish peroxidase (HRP)–tagged anti-His6 antibody. At least three repeats were performed with similar results (*, t test, P < 0.05 relative to the yCD group)

Back to article page